Smartwatch ECG tracing and ischemic heart disease. ACS Watch Study
CONCLUSIONS
In most patients with acute IHD, smartwatch ECG tracing is a reliable tool to make the diagnosis and guide appropriate medical care. However, due to their intrinsic limitations, inferior myocardial infarctions may be missed and require a conventional 12-lead ECG to rule them out. (Source: Cardiology)
Source: Cardiology - November 21, 2022 Category: Cardiology Source Type: research
Two electrocardiographic aberrations important for all caring for patients to know about
Two electrocardiographic (ECG) aberrations encountered daily in ECG interpretation/overreading, which appear to be either unknown, or ignored, by all caring for patients, are described herein: the 1st is the transient increase in the amplitude of QRS complexes in the right precordial ECG leads, leading to the erroneous diagnosis of left ventricular hypertrophy, often encountered in patients with episodes of supraventricular tachycardia, rapid sinus tachycardia, and atrial fibrillation; the 2nd is the spurious ST-segment elevations in lateral and/ or inferior ECG leads in patients with right bundle branch block, interpreted...
Source: Cardiology - November 18, 2022 Category: Cardiology Source Type: research
Analysis of left atrial function after percutaneous intramyocardial septal radiofrequency ablation in hypertrophic cardiomyopathy
Conclusion: PIMSRA is effective in the amelioration of LA reservoir and conduit function in patients with HCM, but not in a marked improvement of LA contraction function in these individuals in short term. (Source: Cardiology)
Source: Cardiology - November 14, 2022 Category: Cardiology Source Type: research
Percutaneous Coronary Intervention for Coronary Ostial lesions Now and Then
n/a (Source: Cardiology)
Source: Cardiology - November 8, 2022 Category: Cardiology Source Type: research
How should weight control and caloric intervention be implemented for obese heart failure patients?
Not required. (Source: Cardiology)
Source: Cardiology - November 2, 2022 Category: Cardiology Source Type: research
Vernakalant for Cardioversion of Recent-Onset Atrial Fibrillation in the Emergency Department: The SPECTRUM Study
Conclusion: Intravenous vernakalant was well tolerated with similar cardioversion rates in patients treated in the ED or non-ED setting and does not require admission to a coronary care unit or intensive care unit. First-line treatment with vernakalant could allow an early discharge in patients with recent-onset AF treated in the ED.Cardiology (Source: Cardiology)
Source: Cardiology - October 25, 2022 Category: Cardiology Source Type: research
Treatment and 30-day mortality after myocardial infarction in prostate cancer patients: A population-based study from Norway
Conclusion: Except for patients with metastatic PCa experiencing an ST-segment elevation AMI, PCa patients were treated as frequent with invasive treatment for their AMI as the general AMI population. 30-day all-cause mortality was lower after AMI in PCa patients compared to the general AMI population. (Source: Cardiology)
Source: Cardiology - October 19, 2022 Category: Cardiology Source Type: research
The ratio of urine N-terminal pro b-type natriuretic peptide to cyclic guanosine monophosphate predicts emergency department visits for heart failure
This study aims to compare the predictive values of urine NT-proBNP/cGMP ratio versus plasma NT-proBNP for ED visits for decompensated HF.
Methods: This prospective study included 126 HF patients with reduced left ventricular ejection fraction (LVEF) ( (Source: Cardiology)
Source: Cardiology - October 12, 2022 Category: Cardiology Source Type: research
Real-World Data on Potent P2Y12 Inhibition in Patients with Suspected Chronic Coronary Syndrome, Referred for Coronary Angiography
Discussion: In patients with CCS referred for CA and PCI if feasible, a more potent P2Y12 inhibition strategy with ticagrelor was not associated with bleeding complications or MACE compared with clopidogrel. (Source: Cardiology)
Source: Cardiology - October 10, 2022 Category: Cardiology Source Type: research
Real-world data on potent P2Y12-inhibition in patients with suspected chronic coronary syndrome, referred for coronary angiography
Conclusion
In patients with CCS referred for CA and PCI if feasible, a more potent P2Y12 inhibition strategy with ticagrelor was not associated with bleeding complications or MACE compared with clopidogrel. (Source: Cardiology)
Source: Cardiology - October 10, 2022 Category: Cardiology Source Type: research
Metformin can be safely used in patients exposed to contrast media: a systematic review and meta-analysis
Conclusion: Metformin can be safely applied in patients with moderate renal impairment as low as eGFR ≥30 ml/min/1.73 m2 during the exposure of the CM. (Source: Cardiology)
Source: Cardiology - October 6, 2022 Category: Cardiology Source Type: research
The value of sacubitril/valsartan in acute anterior wall ST-segment elevation myocardial infarction before emergency Percutaneous coronary intervention
Conclusions: In patients with acute anterior wall STEMI undergoing emergency PCI, preprocedural initiation of Sacubitril/valsartan therapy increased LVEF and lower NT-pro-BNP concentrations compared with valsartan therapy. (Source: Cardiology)
Source: Cardiology - October 5, 2022 Category: Cardiology Source Type: research
Cabergoline-induced hypoprolactinemia may attenuate cardiometabolic effects of atorvastatin: a pilot study
Conclusion: Coexisting hypoprolactinemia may have an unfavorable impact on pleiotropic effects of statins. (Source: Cardiology)
Source: Cardiology - October 4, 2022 Category: Cardiology Source Type: research
The obesity paradox in heart failure: is it still valid in light of new therapies?
This article is a narrative re view on the relationship between body weight and outcomes in patients with HF with special focus on new HF treatments. PubMed was searched for studies reporting the prognostic impact of obesity in HF from 2002 to February 22nd 2022. More than 400 records were examined, with 150 being included in the present review. Literature provides evidence for an obesity paradox in a broad range of HF patients, including acute and chronic HF across the spectrum of left ventricular ejection fraction. It has been verified in HF patients treated with SGLT2i but not in those using sacubitril/valsartan. Cardio...
Source: Cardiology - October 4, 2022 Category: Cardiology Source Type: research
Hyponatremia in patients with heart failure beyond the neurohormonal activation associated with reduced cardiac output: A holistic approach
Abstract
Background: Heart failure (HF)is considered an epidemic disease with considerable morbidity, mortality and immense healthcare costs. Electrolyte abnormalities are often encountered in patients with HF posing a diagnostic and therapeutic challenge for clinicians. Hyponatremia affects up to one third of HF patients and represents an unfavorable prognostic factor.
Summary: Low sodium levels in HF are mainly attributed to the neurohormonal activation secondary to decreased effective circulating volume. However, patients with HF often have several co-morbidities which may cause or exacerbate the pre-existing hyponatr...
Source: Cardiology - September 21, 2022 Category: Cardiology Source Type: research
